Glycogen Storage Disease: Workup and Treatment
Initial Diagnostic Workup
When a patient presents with hypoglycemia and hepatomegaly, immediately obtain critical blood samples including glucose, lactate, uric acid, liver function tests, creatine kinase (CK), lipid profile, plasma carnitine (total and free), acylcarnitine profile, plasma amino acids, urinalysis, and urine organic acids. 1
Key Laboratory Findings by GSD Type
- Elevated transaminases (often >500 IU/L) with elevated CK strongly suggest GSD Type III with myopathy 1
- Normal or mildly elevated liver enzymes with markedly elevated lactate, uric acid, and triglycerides suggest GSD Type I 2
- Ketotic hypoglycemia with elevated beta-hydroxybutyrate distinguishes GSD from fatty acid oxidation disorders (which present with hypoketotic hypoglycemia) 1
Functional Testing
- Glucagon stimulation test: Administer glucagon 2 hours after a carbohydrate-rich meal (should provoke normal glucose rise), then repeat after overnight fast (typically no glucose rise in GSD III, minimal rise in GSD I) 1
Confirmatory Diagnosis
- Genetic testing is the gold standard: Full gene sequencing of G6PC (GSD Ia) and SLC37A4 (GSD Ib) for Type I; AGL gene for Type III 2
- Liver biopsy (if performed) shows fat and glycogen deposition without fibrosis; enzyme activity measurement on frozen tissue can confirm diagnosis but will not detect GSD Ib 2
- Muscle/nerve biopsy may be needed when myopathy is prominent, showing abnormal glycogen accumulation 1
Treatment: Dietary Management (Primary Therapy)
The cornerstone of treatment is preventing hypoglycemia through frequent feedings and maintaining blood glucose ≥70 mg/dL at all times. 2
Infants and Young Children (GSD Type I)
- Avoid fasting >3-4 hours 2
- Use sucrose-free, fructose-free, lactose-free formula (e.g., soy-based like Prosobee) fed every 2-3 hours 2
- Macronutrient distribution: 60-70% carbohydrates (complex, high-fiber), 10-15% protein, <30% fat 2
- Nasogastric or gastric tube placement is recommended for emergency access and overnight continuous gastric feedings; use caution with surgical G-tube in GSD Ib due to infection risk from neutropenia 2
- Introduce raw, uncooked cornstarch between 6-12 months of age (amylase activity may be suboptimal before 12 months) 2
- Continuous overnight gastric feedings calculated to provide glucose infusion rate of 8-10 mg/kg/min in infants, 4-8 mg/kg/min in older children 2
Adolescents and Adults (GSD Type I)
- Avoid fasting >5-6 hours using raw, uncooked cornstarch and/or overnight gastric feedings 2
- Do not change cornstarch brands without careful blood glucose monitoring afterward 2
- Small, frequent meals with same macronutrient distribution (60-70% carbohydrates, 10-15% protein, <30% fat) 2
- Strictly avoid or limit sucrose, fructose, and galactose 2
- Supplement with multivitamins, calcium, and vitamin D due to dietary restrictions 2
GSD Type III Dietary Approach (Different from Type I)
- Higher protein intake (25% of calories) with 45% carbohydrates and 30% fat, as gluconeogenesis is intact 3
- Frequent high-protein feedings during day with high-protein snack at night 3
- Cornstarch supplementation may be beneficial but protein is emphasized over additional cornstarch 1
Critical Treatment Principles
Blood Glucose Monitoring
- Target range: 70-140 mg/dL with levels kept consistent to avoid fluctuations 2
- Monitor before each feed, before cornstarch doses, at bedtime, and first thing in morning 4
- Additional checks during illness, schedule changes, and random checks to detect asymptomatic hypoglycemia 4
Avoiding Treatment Errors
- Both overtreatment and undertreatment are harmful: Overtreatment causes insulin resistance, obesity, and worsens metabolic control 2
- Good glucose control improves metabolic sequelae including reducing adenoma risk 2
Long-Term Surveillance and Complications
Hepatic Monitoring (Primarily GSD Type I)
- Hepatocellular adenomas (HCAs) occur in 16-75% of patients, typically appearing in second-third decade; prevalence increases with age (70-80% of patients >25 years have at least one lesion) 2
- Regular liver imaging (ultrasound, MRI, or CT) to monitor for adenomas and hepatocellular carcinoma (HCC) 2
- Avoid estrogen-based contraceptives when possible as they may promote adenoma growth 2
- HCC risk: Adenoma-to-HCC transformation can occur; no effective biomarker exists 2
Musculoskeletal/Neuromuscular (Primarily GSD Type III)
- Physical therapy evaluation every 6 months or more frequently based on functional status 1
- Neuromuscular consultation at diagnosis with follow-up as symptoms change 1
- EMG/nerve conduction studies if polyneuropathy or intrinsic hand weakness develops 1
- Assess for carpal tunnel syndrome as a treatable cause of hand weakness 1
Special Situations
Surgery/Anesthesia
- Avoid prolonged preoperative fasting based on individual's usual dietary tolerance 1
- Intravenous glucose infusion (typically D10) during and after surgery until oral intake resumes 1
- Monitor blood glucose closely throughout perioperative period 1
Pregnancy
- Maintain euglycemia throughout pregnancy to avoid fetal demise from maternal ketosis 1
- May require continuous nasogastric feeds, cornstarch every 4-6 hours, or central hyperalimentation 1
- Adequate protein intake essential to support gluconeogenesis 1
- Liver imaging before pregnancy and after delivery to monitor adenoma size changes 1
- Planned delivery in tertiary care facility with D10 infusion during labor and postpartum 1
Medication Precautions
- Avoid beta-blockers (or use with extreme caution) as they mask hypoglycemia symptoms, especially problematic in patients with cardiomyopathy 1
- Avoid statins as they can worsen or unmask myopathy 1
- Caution with any drugs causing hypoglycemia 1
Essential Patient Safety Measures
- Medic-Alert bracelets and emergency letters for hypoglycemia management 1
- Routine immunizations including hepatitis B 1
- Metabolic dietitian is essential team member; consult if not available 2